The Pathophysiology of Saturated Fat and Coconut Oil Consumption: A Comprehensive Review of Lipidology, Cardiometabolic Risk, and Physiological Redundancy

The clinical understanding of dietary fats has undergone significant scrutiny over the past century, transitioning from a generalized “low-fat” message to a sophisticated, quality-centric paradigm. Within this landscape, coconut oilCoconut oil is a cooking fat that got marketed as a superfood despite being very high in saturated fat. has emerged as a focal point of intense debate, often characterized by a stark divide between commercial “superfood” marketing and rigorous clinical lipidology. Proponents of coconut oil frequently argue that its unique fatty acid profile confers metabolic advantages, particularly concerning weight lossWeight loss means reducing body fat, whether through food changes, exercise, medication, or surgery., thyroid health, and antimicrobial resistance, while simultaneously challenging the established link between saturated fatty acids and atherosclerotic cardiovascular diseaseCardiovascular disease is the umbrella term for problems with the heart and blood vessels, including heart attacks, strokes, and blocked leg arteries.. However, a deep dive into peer-reviewed research, genetic studies, and randomized controlled trialsA randomized controlled trial assigns people to a treatment or a comparison group purely by chance, then follows both groups. provides a more nuanced and cautionary perspective. This report examines the biochemical composition of coconut oil, evaluates the causality of low-density lipoproteinsA lipoprotein is a tiny package that carries fat and cholesterol through your bloodstream. Since fat won't dissolve in water, it needs a protein wrapper to travel. in cardiovascular pathology, deconstructs common endocrine and metabolic myths, and addresses the physiological redundancy of dietary saturated fatSaturated fat is the kind that stays solid at room temperature — butter, the fat in red meat, coconut oil, and palm oil. through the lens of de novo lipogenesisDe novo lipogenesis is your liver manufacturing fat from scratch, mostly out of excess carbohydrate..

Biochemical Analysis and the MCT Misconception

The primary justification for the purported health benefits of coconut oil often centers on its classification as a source of medium-chain triglycerides (MCTs)Triglycerides composed of fatty acids with 6–12 carbon chains (most clinically relevant preparations focus on C8:0 caprylic and C10:0 capric acids), which are absorbed more rapidly than long-chain fats, preferentially enter portal circulation, and undergo hepatic beta-oxidation; commercial MCT oils are distinct from coconut oil, which is dominated by the borderline C12:0 lauric acid rather than C…. To evaluate this claim, one must analyze the specific carbon chain lengths of the fatty acids that comprise the oil. Coconut oil is predominantly saturated fat (commonly reported in the range of ~84–92% of total fatty acids, depending on processing and analytic method) [1-3]. The predominant fatty acid is lauric acid (C12:0)A 12-carbon saturated fatty acid that constitutes roughly 45–53% of coconut oil's total fatty acids; although sometimes classified as a medium-chain fatty acid, it behaves metabolically more like a long-chain saturated fat, is partly transported via the lymphatic system in chylomicrons, and is among the most potent dietary raisers of LDL-cholesterol when substituted isocalorically for unsaturated…, representing roughly 45% to 53% of total fatty acids in most compositional analyses [1-3].

A critical distinction exists between true medium-chain fatty acids, such as caprylic acid (C8:0)An 8-carbon saturated fatty acid found in small amounts in coconut oil (~7–9%) and concentrated in purified MCT oils; it is rapidly absorbed, transported directly via the portal vein, and oxidized in the liver, accounting for most of the thermogenic and ketogenic effects attributed to MCT preparations in research studies. and capric acid (C10:0), and the “borderline” medium-chain lauric acid (C12:0). In clinical nutrition, MCTs are often operationally defined by their relatively rapid absorption and oxidation compared with long-chain triglyceridesTriglycerides are the main form of fat in your blood and in your body's storage., and by a greater propensity—especially for C8:0 and C10:0—to enter the portal circulation and undergo hepatic beta-oxidationThe metabolic process in liver cells by which fatty acids are broken down within mitochondria to generate acetyl-CoA and energy; shorter-chain fatty acids such as C8:0 and C10:0 enter this pathway more readily than longer-chain saturated fats, which is the biochemical basis for the thermogenic effects ascribed to true MCT oils. [4]. This metabolic pathway is one reason concentrated MCT preparations have been investigated for effects on energy expenditure and satietyThe feeling of fullness and suppression of appetite following a meal; protein is the most satiating macronutrient per calorie, and higher-protein diets exploit this property to reduce total energy intake and support weight loss. [4]. However, human metabolic studies demonstrate that medium-chain fatty acids can still be incorporated into chylomicronA chylomicron is a very large particle that carries fat from a meal out of your intestines and into your bloodstream. triglycerides, and the extent of lymphatic transport increases with chain length (with C12:0 behaving more like a long-chain fatty acid than C8:0/C10:0) [5]. Accordingly, the mechanistic effects reported for purified MCT oils enriched almost exclusively in C8:0 and C10:0 should not be automatically extrapolated to whole coconut oil, which is dominated by C12:0 and also contains substantial myristic acid (C14:0)A 14-carbon saturated fatty acid present at 16–21% in coconut oil; alongside lauric acid, it is considered one of the most potent LDL-cholesterol–raising saturated fatty acids in the diet when exchanged for cis-unsaturated fats. and palmitic acid (C16:0) [1-3].

Fatty Acid Composition of Coconut Oil vs. Other Fats

The following table details the fatty acid profiles of common dietary fats, highlighting the unique concentration of C12:0 and C14:0 in coconut oil compared to animal fats and vegetable oils (values are approximate ranges drawn from food composition analyses and lipid chemistry references) [1-3].

Figure 1. Stacked-bar schematic of approximate fatty acid composition (midpoint values shown) for selected fats; this chart is illustrative and is intended to make the tabulated ranges visually comparable, not to substitute for primary compositional analytics.

As shown, the concentration of shorter-chain MCFAs (C8:0 and C10:0) in coconut oil is modest relative to C12:0 [1-3]. The high levels of lauric and myristic acids are particularly relevant to clinical lipidology, as these saturated fatty acids are among the most potent dietary modulators of LDL-cholesterol raising when exchanged isocalorically for cis-unsaturated fats [6,9].

The Causal Role of Low-Density Lipoproteins in Atherosclerosis

One of the most persistent claims in the popular press is that the link between saturated fat and heart disease is based solely on flawed epidemiological data. This assertion ignores decades of advancements in genetic research, randomized controlled trials (RCTs), and basic science. The European AtherosclerosisAtherosclerosis is the disease behind most heart attacks and many strokes. Cholesterol particles get stuck in the wall of an artery, the body sends immune cells to clean up, and over years that mess hardens into plaque. Society (EAS) Consensus Panel has summarized evidence that low-density lipoproteins (LDLLDL, or low-density lipoprotein, is the main particle that carries cholesterol through your blood — and the main one that gets stuck in artery walls.) are not merely markers of risk, but causal agents in the development of atherosclerotic cardiovascular disease (ASCVD) [10].

Evidence from Genetic and Mendelian Randomization Studies

Mendelian randomizationMendelian randomization is a clever research method that uses the genes people were born with as a natural experiment. and other genetic approaches provide tools for causal inference by leveraging genetic variants that influence LDL-C levels from birth. Across multiple genetic mechanisms that lower LDL-C, lifetime exposure to lower LDL-C is consistently associated with proportionally lower ASCVD risk, supporting a “cumulative LDL burden” framework for plaquePlaque is the buildup of cholesterol, immune cells, scar tissue, and calcium inside an artery wall. initiation and progression [10].

Results from Randomized Controlled Trials

Randomized trials of LDL-lowering therapies (e.g., statinsA statin slows the enzyme your liver uses to make cholesterol. Your liver responds by pulling more cholesterol out of your blood, which is where the real benefit comes from., ezetimibeEzetimibe is a pill that blocks your intestines from absorbing cholesterol., PCSK9 inhibitorsA PCSK9 inhibitor is a medicine that blocks that cholesterol-destroying protein, leaving more docking ports available to clear particles from the blood.) demonstrate dose-dependent reductions in major vascular events with LDL-C lowering. The CholesterolCholesterol is a waxy substance your body needs. It goes into cell walls, hormones, vitamin D, and the bile that digests your food. You would die without it. Treatment Trialists’ (CTT) Collaboration reported that each ~1.0 mmol/L reduction in LDL-C reduces the annual rate of major vascular events by just over one fifth, with no evidence of a lower threshold within the ranges studied [11]. Dietary feeding trials and pooled evidence also support that replacing saturated fats with polyunsaturated fatsPolyunsaturated fat is found in seed oils, nuts, seeds, and fish. Omega-3 and omega-6 fats both belong to this family. lowers LDL-C and reduces coronary events, whereas replacement with refined carbohydrateCarbohydrates are the sugars and starches in food — bread, rice, pasta, fruit, potatoes, sweets. does not reliably improve outcomes [9].

Coconut oil consumption has been shown in meta-analyses of RCTs to increase LDL-C compared with non-tropical unsaturated vegetable oils, while often also increasing HDL-C [6,7]. Although the LDL-C increase may be smaller than that observed with butter in some comparisons, it is consistently less favorable than replacement with cis-unsaturated oils such as olive, safflower, sunflower, soybean, and canola oils [6-8].

Lipid Profile Comparison: Coconut Oil vs. Other Fat Sources

Figure 2. Schematic bar chart reflecting the *directionality* of lipid changes reported in randomized comparisons; this figure is not intended to represent absolute unit changes and should be interpreted alongside the cited meta-analyses and trials.

The clinical significance of these changes must be interpreted through the lens of causality. Because LDL-C reflects exposure to atherogenic apoB-containing lipoproteins and LDL is causal in atherosclerosis, LDL-C increases associated with coconut oil consumption plausibly increase absolute ASCVD risk, regardless of simultaneous HDL-C increases [9-11].

The ApoBApoB is a protein that sits on the outside of every cholesterol particle that can get stuck in your artery wall and cause plaque. Each of those particles carries exactly one ApoB. Paradigm and the “Large Fluffy LDL” Myth
A common defense of coconut oil is the claim that it primarily raises “large, fluffy” LDL particles (Pattern A), which are allegedly not atherogenic, rather than “small, dense” LDL particles (Pattern B). This narrative is increasingly viewed as an oversimplification. The atherogenicity of apoB-containing lipoproteins is primarily driven by the number of particles capable of entering and being retained within the arterial intimaThe intima is the innermost layer of an artery wall, sitting just beneath the smooth lining., not by a reassuring label of “large” or “small” particles [12,13].

Each atherogenic particleAtherogenic particles are the ApoB-containing lipoproteins—including LDL, IDL, VLDL, and lipoprotein(a)—that can enter and be retained in the artery wall to initiate and sustain plaque growth; the article uses the term to describe what must be lowered substantially and sustainably to achieve plaque regression.—whether VLDLVLDL, or very-low-density lipoprotein, is the particle your liver makes to ship triglycerides out to the rest of the body., IDLIDL, or intermediate-density lipoprotein, is a particle that forms partway through the process of a big triglyceride-carrying particle shrinking down into an LDL particle., or LDL—contains exactly one molecule of apolipoproteinAn apolipoprotein is a protein attached to a fat-carrying particle in your blood. Fat and water don't mix, so these proteins act like a wrapper that lets fat travel safely through the bloodstream. B (apoB). Therefore, apoB concentration is a direct measure of the total number of atherogenic particles [12,13]. DiscordanceSee ApoB Discordance for the full entry. analyses have shown that when LDL-C and apoB provide different risk estimates, ASCVD risk more closely tracks apoB [12,13]. A recent scientific review of discordance evidence concluded that apoB is a more accurate marker of cardiovascular risk than LDL-C or non–HDL-C when these measures disagree [12].

Coconut oil has been reported to raise LDL-C in clinical trialsA clinical trial is a study where researchers give one group a treatment and another group a placebo or standard care, then compare what happens. and meta-analyses; when LDL-C rises, apoB often rises in parallel, particularly in patterns characterized by increased apoB particle exposure over time [6,12,13]. Accordingly, focusing on particle “size” without accounting for apoB particle number risks misclassifying lipid-mediated ASCVD risk.

The HDL Paradox and Functional Limitations

Another central pillar of the “healthy coconut oil” argument is its ability to raise HDL-C levels. While observational studies historically showed an inverse relationship between HDL-C and cardiovascular events, pharmacological attempts to reduce ASCVD by raising HDL-C have not produced consistent benefit. In the dal-OUTCOMES trialA randomized trial of dalcetrapib, a CETP inhibitor that raised HDL-cholesterol, which found no reduction in cardiovascular events after acute coronary syndrome, contributing to evidence that pharmacologically increasing HDL-C does not reliably translate into clinical benefit., dalcetrapib increased HDL-C but did not reduce cardiovascular events after acute coronary syndromeAcute coronary syndrome (ACS) is the umbrella term for any sudden drop in blood flow to the heart — from unstable angina to a full heart attack — caused by a plaque suddenly rupturing or eroding. [14]. In the ACCELERATE trialA large randomized trial of evacetrapib that substantially raised HDL-cholesterol and lowered LDL-cholesterol yet failed to reduce cardiovascular outcomes in high-risk patients, further supporting the view that HDL-C is a marker rather than a causal protective factor., evacetrapib substantially raised HDL-C and lowered LDL-C, yet did not reduce cardiovascular outcomes in high-risk patients [15]. In AIM-HIGH, adding extended-release niacinNiacin is vitamin B3, which at very high doses lowers LDL and raises HDL. to intensive statin therapy increased HDL-C but did not reduce cardiovascular events [16]. Similarly, in HPS2-THRIVE, niacin/laropiprant added to statin-based therapy did not significantly reduce major vascular events and increased adverse events [17].

Mendelian randomizationRandomization is the process of assigning trial participants to treatment or control groups by chance, ensuring that known and unknown confounding factors are evenly distributed; when randomization fails—as auditors found occurred in PREDIMED—the groups may differ in ways that distort the apparent treatment effect. also challenges the assumption that higher HDL-C is causally protective. In a landmark study, genetic mechanisms that raise HDL-C did not uniformly lower myocardial infarctionSee Heart Attack for the full entry. risk, undermining the view that simply raising HDL-C will translate into benefit [18].

These findings support the concept that HDL-C is more a marker of metabolic context than a direct causal protective factor. The protective properties of HDL may relate more to functional measures such as macrophage cholesterol efflux capacity (CEC)A functional measure of HDL's ability to accept cholesterol from macrophage foam cells in the arterial wall for transport back to the liver; it correlates with cardiovascular protection independently of HDL-C levels, suggesting that HDL function matters more than HDL quantity.. In a study of HDL function and atherosclerosis, CEC was inversely associated with carotid intima–media thickness and coronary disease status independent of HDL-C level [19]. Saturated fats may increase HDL-C without necessarily improving HDL functionality. Therefore, HDL-C increases with coconut oil do not “cancel out” LDL-related risk [10-12,18,19].

Deconstructing Endocrine and Metabolic Claims

Beyond lipidology, coconut oil is frequently promoted for its effects on weight loss, thyroid function, and testosteroneTestosterone is the main male sex hormone, though women produce it too in smaller amounts. levels. Peer-reviewed research, however, indicates that many of these claims are based on mechanistic overreach, conflation with purified MCT preparations, or misinterpretations of pharmacologic studies.

Weight Loss and Adiposity

The claim that coconut oil aids in weight loss is frequently derived from studies of purified MCT oils enriched in C8:0 and C10:0, which can increase postprandial thermogenesisThe increase in energy expenditure that occurs after a meal as the body processes and metabolizes food; purified MCT oils rich in C8:0 and C10:0 produce a modestly greater postprandial thermogenic response than long-chain fats, an effect that has been incorrectly generalized to coconut oil in weight-loss marketing. and satiety relative to long-chain fats in some settings [4]. However, systematic reviewsA systematic review searches for every study on a question using a pre-declared method, then assesses them by consistent criteria. and meta-analyses of trials specifically evaluating coconut oil show no clinically meaningful reductions in body weight, BMI, or waist circumferenceWaist circumference is simply the measurement around your middle, taken at the level of your belly button. compared with other dietary fats, with findings often heterogeneous and sensitive to study design and whether coconut oil replaces (versus adds to) other calories [20,21].

A major factor is the “calorie displacement” issue: if coconut oil is added on top of baseline intake rather than substituted isocalorically for other fats, total energy intake increases and any small thermogenic differences become clinically negligible [20]. Additionally, coconut oil’s dominance of C12:0 and C14:0 differentiates it from purified MCT oils, making large extrapolations from C8:0/C10:0 studies biologically tenuous [1,4,5].

The Thyroid–Butyrate Fallacy

A recurrent claim in non-scholarly sources is that coconut oil contains butyric acid and that this allegedly improves thyroid function by increasing T3 uptake in glial cells. This claim is inaccurate on composition and mechanism:

Chemical composition: Coconut oil contains negligible butyric acid (C4:0); butyrateA short-chain fatty acid produced when gut bacteria ferment dietary fiber; it strengthens the intestinal barrier, reducing the leakage of bacterial toxins (such as LPS) into the bloodstream that would otherwise drive systemic inflammation. is primarily associated with ruminant milk fat and with microbial fermentation of dietary fiberFiber is the part of plant food your body cannot digest. It is found in beans, oats, vegetables, fruit, and whole grains. in the colon [2,3].
Mechanistic confusion: The “butyrate/T3 uptake” narrative appears to conflate dietary butyrate with sodium phenylbutyrate, a pharmacologic chemical chaperone. Sodium phenylbutyrate has been studied in cellular models of monocarboxylate transporter 8 (MCT8) deficiency for its ability to rescue thyroid hormone transport defects [22]. There is no clinical evidence that consuming coconut oil (which lacks meaningful butyrate) improves thyroid hormone transport or T3 uptake in the brain.

Testosterone and Dietary Fat

The relationship between dietary fat and testosterone is often cited as a reason to consume high amounts of saturated fat. While very low-fat diets can modestly reduce testosterone in some intervention studies, this does not establish a requirement for high saturated fat intake. A systematic review and meta-analysisA meta-analysis statistically combines the results of many separate studies into one overall estimate. comparing low-fat versus higher-fat diets in men found lower testosterone on low-fat diets, though study sizes were small and levels often remained within reference ranges [23].

In clinical practice, excess adiposity is a dominant, modifiable driver of low testosterone in men via multiple pathways, including changes in sex hormone–binding globulin and increased aromatization in adipose tissue. Meta-analytic data show that weight loss—especially with larger magnitude loss—can significantly increase testosterone concentrations, with the degree of weight loss predicting the rise in testosterone [24,25]. Therefore, for men concerned about testosterone, sustainable weight loss and cardiometabolic risk reduction are typically more impactful than increasing saturated fat intake, which may worsen atherogenic lipoprotein exposure [9-12,24,25].

Antimicrobial and Antiviral Potential: Lab vs. Life

The antimicrobial and antiviral claims for coconut oil often cite lauric acid and monolaurin effects on lipid-coated pathogens in vitro. While these mechanisms are biologically plausible and robust in laboratory settings, translation through dietary intake to meaningful systemic infection prevention in humans remains uncertain. Clinical studies have explored virgin coconut oil (VCO) as adjunct therapy in COVID-19, reporting improvements in inflammatory markers such as C-reactive proteinC-reactive protein, or CRP, is a substance your liver makes when there is inflammation somewhere in your body. A sensitive version of the test, hs-CRP, is used to estimate heart risk. (CRP) and symptom timelines in small trials [26,27]. However, these studies are limited by sample size, setting, and adjunctive-care context; larger, well-controlled trials would be necessary before positioning VCO as an evidence-based systemic antimicrobial strategy [26,27]. Many traditional and supported uses of coconut-derived lipids remain topical (e.g., skin barrier and dermatologic applications) rather than systemic disease prevention.

De Novo Lipogenesis: The Physiological Redundancy of SFA

A central question in the discussion of saturated fat is whether the human body requires dietary intake of saturated fatty acids. From a physiological standpoint, saturated fatty acids are not essential nutrients because the human body can synthesize saturated and monounsaturated fatsMonounsaturated fat is the main fat in olive oil, avocados, and most nuts. de novo. De novo lipogenesis (DNL) occurs primarily in liver and adipose tissue, converting excess carbohydrate substrates into fatty acids, with palmitate (C16:0) a major end-product that can be stored, oxidized, elongated, or desaturated for structural and signaling needs [28,29].

Research in human adipocyte models demonstrates that preadipocytes can differentiate and accumulate triacylglycerol even in the complete absence of exogenous fat, with DNL providing saturated fatty acids (including 12:0 through 18:0) and, via desaturation, monounsaturated fatty acids required for normal lipid droplet formation and cellular maturation [30]. In humans, higher-carbohydrate feeding can markedly increase DNL flux under specific metabolic conditions, underscoring that endogenous fatty acid synthesis can maintain saturated fat pools even when dietary saturated fat intake is low [28,31].

Because the body can synthesize saturated fat, there is no established minimum dietary requirement for saturated fatty acids. This contrasts with essential fatty acids (e.g., linoleic acid and alpha-linolenic acid), which humans cannot synthesize and must obtain from the diet [32].

All-Cause Mortality and the Replacement Paradigm

The impact of dietary fat on longevity is a critical endpoint in nutritional science. While cardiovascular-specific outcomes are central, evidence on all-cause mortalityAll-cause mortality means death from any cause at all, not just heart disease — the broadest, hardest-to-game outcome a study can measure. further supports that fat “quality” and substitution patterns matter.

Evidence from Large-Scale Cohort Studies

In the NIH-AARP Diet and Health Study (over 521,000 participants followed for 16 years), higher saturated fat intake was associated with higher total mortality, whereas isocaloric replacement of saturated fat with unsaturated fatsUnsaturated fat is liquid at room temperature and comes from plants and fish — olive oil, nuts, seeds, avocado, seed oils. was associated with lower mortality risk [33]. Other large prospective cohortsA prospective cohort enrolls healthy people, records their characteristics, and then waits to see what happens. similarly report divergent associations of dietary fat types with mortality, supporting the replacement of saturated and trans fatsTrans fat is an artificially altered fat once used to make processed foods last longer on the shelf. with unsaturated fats [34]. (As with all observational evidence, residual confoundingConfounding is when a hidden third factor makes two unrelated things look connected. is possible; nonetheless, consistency with lipid-mediated mechanisms strengthens plausibility.)

Contradictory Findings in Recent Meta-Analyses

Systematic reviews of RCTs have sometimes found limited effects of saturated-fat reduction on all-cause mortality, particularly when follow-up is short and when the replacement nutrient is not specified. However, RCT evidence more consistently shows reductions in composite cardiovascular events when saturated fats are reduced and replaced with polyunsaturated fats, rather than with refined carbohydrate [9,35]. These patterns reinforce that “replacement specificity” is not an academic nuance but a determinant of measurable benefit.

Global Health Guidelines and the Misinformation Surge

Global health authorities remain consistent that saturated fat should be limited and that replacement with unsaturated fats is preferred. The World Health Organization recommends limiting saturated fat intake and emphasizes replacing saturated fats with unsaturated fats as part of a healthy diet pattern [32]. The American Heart Association similarly recommends replacing saturated fats with polyunsaturated and monounsaturated fats to reduce cardiovascular risk [9].

Summary of Major Health Guidelines

Organization | Saturated Fat Recommendation | Primary Goal

WHO | Limit saturated fat; replace with unsaturated fats [32] | Prevention of non-communicable diseases
AHA | Emphasize replacement of saturated fat with unsaturated fats [9] | Reduction of ASCVD risk

The persistence of pro–coconut oil narratives is facilitated by confusion between surrogate markersA surrogate marker is a stand-in measurement used because the thing you really care about takes too long to observe. (e.g., HDL-C) and causal pathways and clinical endpoints (e.g., apoB particle exposure, myocardial infarction, strokeA stroke happens when blood flow to part of the brain stops, either from a blockage or from bleeding.). While short-term studies may show favorable changes in selected biomarkersA biomarker is something measurable in the body that tells you about health or disease — a lab value, a scan result, a blood pressure reading., the best-supported lipid-causal framework and RCT/meta-analytic evidence indicate that coconut oil raises LDL-C relative to unsaturated vegetable oils, which is not aligned with a heart-healthy replacement strategy [6-12].

Conclusion

The comprehensive analysis of peer-reviewed research regarding coconut oil and saturated fat reveals a significant gap between public perception and scientific reality. Coconut oil is a concentrated source of saturated fatty acids that increases LDL-C compared with non-tropical unsaturated oils in randomized trials and meta-analyses, and LDL-related apoB particle exposure is causal in ASCVD [6,7,10-13]. The parallel increase in HDL-C does not establish cardiovascular protection, given failed HDL-raising trials and Mendelian randomization evidence indicating that raising HDL-C is not necessarily causal for lowering myocardial infarction risk [14-18].

Furthermore, the purported benefits of coconut oil for weight loss, thyroid function, and endocrine optimization are either weakly supported, inconsistent in human trials, or based on conflation with different compounds or purified MCT preparations [20-23]. Finally, the body’s capacity for de novo lipogenesis renders dietary saturated fat physiologically non-essential; essential fatty acids are instead obtained from unsaturated fat sources [28-32]. For individuals seeking to optimize cardiovascular health and overall longevity, the evidence supports replacing saturated fats, including coconut oil, with plant-based unsaturated oils shown to improve lipid profilesA blood test panel that measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, used to assess cardiovascular risk and monitor the effect of dietary or drug interventions. and reduce cardiovascular event risk within broader healthy dietary patterns [9-12,33-35].

References

1. Newport MT, Dayrit FM. Analysis of 26 Studies of the Impact of Coconut Oil on Lipid Parameters: Beyond Total and LDL Cholesterol. Nutrients. 2025;17(3):514. Published 2025 Jan 30. doi:10.3390/nu17030514
2. Bezard J, Bugaut M, Clement G. Triglyceride composition of coconut oil. J Am Oil Chem Soc. 1971;48(3):134-139. doi:10.1007/BF02545736.
3. Marina AM, Man YB, Nazimah SA, Amin I. Antioxidant capacity and phenolic acids of virgin coconut oil. Int J Food Sci Nutr. 2009;60 Suppl 2:114-123. doi:10.1080/09637480802549127
4. Bach AC, Babayan VK. Medium-chain triglycerides: an update. Am J Clin Nutr. 1982;36(5):950-962. doi:10.1093/ajcn/36.5.950
5. Swift LL, Hill JO, Peters JC, Greene HL. Medium-chain fatty acids: evidence for incorporation into chylomicron triglycerides in humans. Am J Clin Nutr. 1990;52(5):834-836. doi:10.1093/ajcn/52.5.834
6. Neelakantan N, Seah JYH, van Dam RM. The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Clinical Trials. Circulation. 2020;141(10):803-814. doi:10.1161/CIRCULATIONAHA.119.043052
7. Duarte AC, Spiazzi BF, Zingano CP, et al. The effects of coconut oil on the cardiometabolic profile: a systematic review and meta-analysis of randomized clinical trials. Lipids Health Dis. 2022;21(1):83. Published 2022 Aug 31. doi:10.1186/s12944-022-01685-z
8. Khaw KT, Sharp SJ, Finikarides L, et al. Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women. BMJ Open. 2018;8(3):e020167. Published 2018 Mar 6. doi:10.1136/bmjopen-2017-020167
9. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation. 2017;136(3):e1-e23. doi:10.1161/CIR.0000000000000510
10. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
11. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5
12. Sehayek D, Cole J, Björnson E, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. J Clin Lipidol. 2025;19(4):844-859. doi:10.1016/j.jacl.2025.05.024
13. Ference BA, Kastelein JJP, Catapano AL. Lipids and Lipoproteins in 2020. JAMA. 2020;324(6):595-596. doi:10.1001/jama.2020.5685
14. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089-2099. doi:10.1056/NEJMoa1206797
15. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017;376(20):1933-1942. doi:10.1056/NEJMoa1609581
16. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. doi:10.1056/NEJMoa1107579
17. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-212. doi:10.1056/NEJMoa1300955
18. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580. doi:10.1016/S0140-6736(12)60312-2
19. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135. doi:10.1056/NEJMoa1001689
20. Swarnamali H, Ranasinghe P, Hills AP, Jayawardena R. Coconut oil consumption and bodyweight reduction: a systematic review and meta-analysis. Minerva Endocrinol (Torino). 2023;48(1):76-87. doi:10.23736/S2724-6507.21.03654-X
21. Gaeini Z, Bahadoran Z, Malmir H, Mirmiran P. Dose-dependent effect of coconut oil supplementation on obesity indices: a systematic review and dose-response meta-analysis of clinical trials. BMC Nutr. 2025;11(1):113. Published 2025 Jun 6. doi:10.1186/s40795-025-01090-6
22. Braun D, Bohleber S, Vatine GD, Svendsen CN, Schweizer U. Sodium Phenylbutyrate Rescues Thyroid Hormone Transport in Brain Endothelial-Like Cells. Thyroid. 2022;32(7):860-870. doi:10.1089/thy.2021.0643
23. Whittaker J, Wu K. Low-fat diets and testosterone in men: Systematic review and meta-analysis of intervention studies. J Steroid Biochem Mol Biol. 2021;210:105878. doi:10.1016/j.jsbmb.2021.105878
24. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829-843. Published 2013 May 2. doi:10.1530/EJE-12-0955
25. Muir CA, Wittert GA, Handelsman DJ. Approach to the Patient: Low Testosterone Concentrations in Men With Obesity. J Clin Endocrinol Metab. 2025;110(9):e3125-e3130. doi:10.1210/clinem/dgaf137
26. Angeles-Agdeppa I, Nacis JS, Capanzana MV, Dayrit FM, Tanda KV. Virgin coconut oil is effective in lowering C-reactive protein levels among suspect and probable cases of COVID-19. J Funct Foods. 2021;83:104557. doi:10.1016/j.jff.2021.104557
27. Angeles-Agdeppa I, Nacis JS, Dayrit FM, Tanda KV. Virgin coconut oil (VCO) supplementation relieves symptoms and inflammation among COVID-19 positive adults: a single-blind randomized trial. J Nutr Sci. 2024;13:e5. Published 2024 Jan 23. doi:10.1017/jns.2023.118
28. Hellerstein MK. De novo lipogenesis in humans: metabolic and regulatory aspects. Eur J Clin Nutr. 1999;53 Suppl 1:S53-S65. doi:10.1038/sj.ejcn.1600744
29. Softic S, Cohen DE, Kahn CR. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. Dig Dis Sci. 2016;61(5):1282-1293. doi:10.1007/s10620-016-4054-0
30. Collins JM, Neville MJ, Pinnick KE, et al. De novo lipogenesis in the differentiating human adipocyte can provide all fatty acids necessary for maturation. J Lipid Res. 2011;52(9):1683-1692. doi:10.1194/jlr.M012195
31. Hudgins LC, Hellerstein MK, Seidman CE, Neese RA, Tremaroli JD, Hirsch J. Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. J Lipid Res. 2000;41(4):595-604.
32. World Health Organization. Healthy diet. Fact sheet. 26 Jan 2026.
33. Zhuang P, Zhang Y, He W, et al. Dietary Fats in Relation to Total and Cause-Specific Mortality in a Prospective Cohort of 521 120 Individuals With 16 Years of Follow-Up. Circ Res. 2019;124(5):757-768. doi:10.1161/CIRCRESAHA.118.314038
34. Wang DD, Li Y, Chiuve SE, et al. Association of Specific Dietary Fats With Total and Cause-Specific Mortality. JAMA Intern Med. 2016;176(8):1134-1145. doi:10.1001/jamainternmed.2016.2417
35. Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2015;(6):CD011737. Published 2015 Jun 10. doi:10.1002/14651858.CD011737